Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Carcinoma; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma
Interventions: Drug: NGM831; Drug: NGM831 plus pembrolizumab
Sponsor: NGM Biopharmaceuticals, Inc
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
February 11, 2022 /
/ in Oncology